JOTEC GmbH develops, produces and markets endovascular stent grafts and cardiac and vascular surgical implants for the treatment of aortic and peripheral vascular diseases.
JOTEC GmbH develops, produces and markets medical devices for the treatment of aortic and peripheral vascular diseases. Founded in 2000 and headquartered in Hechingen, Germany, the company specialises in endovascular stent grafts and in cardiac and vascular surgical implants, and supplies cardiac and vascular surgeons worldwide.
Its product portfolio rests on proprietary polyester and nitinol implant materials technology. Endovascular stent graft systems built on this platform address aortic and peripheral vascular disease, while the E-VITA Open Neo hybrid stent graft system targets complex aortic conditions. Conventional vascular grafts and interventional implants complete the range for cardiac and vascular surgery.
Technical work spans endovascular stent graft technology, hybrid stent graft systems, interventional vascular implants and in-house medical device development and manufacturing. The company describes a working model built on collaboration with leading surgeons and on technologically differentiated products aimed at outcomes in complex aortic aneurysm and dissection treatment.
Since December 2017 JOTEC has been a wholly-owned subsidiary of Artivion, Inc., formerly CryoLife, Inc.
